David Suhy

David is that unique combination of gene therapy expert, experienced in bio ventures both private and public, having brought gene therapy ideas from inception all the way through to Phase 2 clinical trials, and being great leader that science teams love to work with. Before Earli, he was the CSO at Benitec Biopharma with expertise in combining multiple therapeutic modalities (RNAi, antisense RNA, proteins) with gene therapy delivery, and oversaw development path for multiple products in or near term clinical studies including Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC), and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first non-withdrawable, systemic RNAi compound used clinically in human subjects. He held previous scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara and PPD. He holds a PhD in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed his post doctoral training at Stanford. He is a great dad to three teenage children and loves making pizza in his large wood-fired oven in his backyard. His wife Joyce is a neuroscientist who knows the risks of science, and is yet fully convinced that with David’s passion, Earli will accomplish its purpose.